EmergingStrategiesandRulesforT-CellReceptorDerivedTherapy(AReview)

Authors

  • Fakhru Nisa DepartmentAlliedHealthSciencesAHSMedicalLaboratoryTechnology,SuperiorUniversity Lahore, Author
  • Zubair Sharif Faculty of Allied Health Sciences, Superior UniversityLahore Author
  • Hafiz Ayaz Ahmed Faculty of Allied Health Sciences, Superior UniversityLahore Author
  • Sidra Iqbal Faculty of Allied Health Sciences, Superior UniversityLahore Author

DOI:

https://doi.org/10.63163/jpehss.v3i2.290

Abstract

TCR-based   therapies   represent   a   groundbreaking   step   forward   in   cancer   immunotherapy, leveraging the immune system's ability to identify and kill cancer cells. This review explores the latest  strategies  and  regulation  updates  influencing  TCR-targeted  therapies,  presenting  an integrated  picture  of  their  scientific  rationale,  recent  developments,  and  prospective  future directions.  The  review  first  describes  the  fundamental  mechanisms  of  TCR-derived  therapy, highlighting  how  TCRs  recognize  intracellular  tumor-associated  antigens  presented  by  major histocompatibility  complex  (MHC)  molecules.  The  review  then  discusses  some  of  the  main challenges of the field, including antigen specificity, TCR affinity, off-target toxicity, and tumor heterogeneity, which hinder the discovery of safe and effective therapies. New technologies like gene  editing,  synthetic  biology,  and  high-throughput  screening  are  revolutionizing  TCR  design and  delivery  to  target  more  precisely  and  with  improved  safety  profiles.  At  the  same  time, regulatory  mechanisms  are  being  reformatted  to  address  the  challenges  of  engineered  T-cell therapies through revised guidelines and oversight. Clinical trials have also produced promising outcomes,  especially  in  hematologic  malignancies  and  a  few  solid  tumors,  demonstrating  the therapeutic  potential  of  TCR-based  therapies.  Results  from  case  studies  identify  successes  and limitations, giving useful insights to maximize treatment effectiveness. In the future, the review underlines the need to create predictive models,investigatecombination treatments, and provide morewidespreadaccesstopersonalizedimmunotherapies.Withongoingadvancesinresearchand development, TCR-derived therapy has the potential to become the cornerstone of future cancer treatment—subject to scientific, clinical, and regulatory matters being resolved in harmony.

Downloads

Published

2025-06-30